亚砷酸在原发性肝癌介入治疗中的疗效观察

目的观察亚砷酸（As2O3）在原发性肝癌介入治疗中的疗效。方法对43例患者采用Seldinger技术，应用亚砷酸及碘油对原发性肝癌患者进行介入治疗。结果其中无完全缓解（CR）病例，部分缓解（PR）18例、无变化（SD）17例、进展（PD）8例，客观有效率（CR＋PR）41．86％，获益率（CR＋PR＋SD）81．39％。29例血清AFP阳性的患者AFP下降率为55．17％（16／29）。主要毒副反应有发热、食欲减退及腹胀。结论亚砷酸应用于原发性肝癌的介入治疗，疗效确切，操作简单易行，毒副作用小，值得临床推广应用。

Therapeutic effect of arsenic trioxide for primary hepatocellular carcinoma

Objective To evaluate the therapeutic effect of arsenic trioxide in the interventional treatment for primary hepatocellular carcinoma (HCC). Methods Seldinger technique was adopted and 43 patients with primary HCC were treated with arsenic trioxide and iodized oil by the interventional treatment. Results No patients showed complete response (CR), 18 patients showed partial response (PR), 17 stable disease (SD) and 8 progression disease (PD). Of 43 patients, the objective response rate (CR+PR) was 41.86%, the clinical beneficial response rate (CR+PR+SD) was 81,39%. Among the 29 patients with elevated AFP, the AFP descent rate was 55.17%. Major toxic effects were fever, anorexia and abdominal distention. Conclusion Arsenic trioxide in the interventional treatment for primary HCC proves to be reliable, simple, and with little toxic effect.